跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 785 条关于
“choroidal neovascularisation”
全部
785
临床试验
688
药物
10
机构
1
资讯
86
去年
EMA Panel Recommends Aflibercept Biosimilar Eydenzelt for Retinal Disorders
去年
Formycon's Aflibercept Biosimilar (FYB203) Receives Positive CHMP Opinion for EU Approval
去年
CRISPR-Cas9 Reduces VEGF Levels in Monkeys, Shows Retinal Toxicity at High Doses
去年
Sandoz's Aflibercept Biosimilar Afqlir Gains European Commission Approval
去年
European Commission Approves Aflibercept Biosimilar OPUVIZ for Retinal Disorders
去年
European Commission Approves Sandoz's Afqlir, an Aflibercept Biosimilar, for Retinal Diseases
去年
European Commission Approves Sandoz's Afqlir® (aflibercept) Biosimilar for Retinal Diseases
去年
Formycon's Aflibercept Biosimilar FYB203 Receives Positive CHMP Opinion for EU Approval
3个月前
EMA Recommends Approval for Ranibizumab Biosimilar Vislyfa, Expanding European Treatment Options for Retinal Diseases
去年
Formycon's Aflibercept Biosimilar (FYB203) Gains EU Approval for Retinal Diseases
第 1 页,共 9 页
上一页
下一页